



X4 Pharmaceuticals Appoints Adam Mostafa as Chief Financial Officer

September 27, 2018

Mr. Mostafa brings expertise in biotechnology financing and transactional experience to strengthen management team for next stage of company growth

CAMBRIDGE, Mass., September 27, 2018 – [X4 Pharmaceuticals](#), a clinical-stage biotechnology company developing novel [CXCR4](#) allosteric antagonist drug candidates designed to improve immune cell trafficking to treat rare diseases and cancer, announced the appointment of Adam Mostafa as Chief Financial Officer. Mr. Mostafa is an accomplished financial executive with over 17 years of experience in biotechnology-focused corporate finance and transactional experience.

“I am thrilled to welcome Adam to the X4 leadership team as our Chief Financial Officer,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4. “Adam’s broad expertise in developing financing strategies and deep understanding of the financial needs of development stage biotech companies will be invaluable to us as we plan for X4’s next stage of growth.”

“This is an incredibly exciting and pivotal time to join X4 as the company rapidly evolves as a clinical-stage company,” said Mr. Mostafa. “I look forward to working with the talented team at X4 as we execute on our business goals and realize the potential to build a pipeline of innovative rare disease and cancer treatments to make a difference in the lives of patients.”

Most recently, Mr. Mostafa was Chief Financial Officer of Abpro Therapeutics where he was instrumental to achieving key financing and business development objectives during a period of strong growth. Prior to Abpro, Mr. Mostafa was a Managing Director in the Healthcare Investment Banking group at Cantor Fitzgerald where he had relationship responsibility and led transaction origination and execution across the biotechnology sector. Before Cantor, Mr. Mostafa was a senior banker in the Healthcare Investment Banking group at Needham & Company where he led the execution of numerous biotechnology IPOs, follow-on offerings, M&A and other transactions. Earlier in his career, Mr. Mostafa was a Vice President in the Biotechnology Investment Banking group at CRT Capital Group and was a Portfolio Management Associate in the Global Stock Selection group at AQR Capital Management, a large global hedge fund. Mr. Mostafa started his career as an analyst in the Healthcare Investment Banking group at Salomon Smith Barney. Mr. Mostafa earned an A.B. in Economics from Brown University.

About X4 Pharmaceuticals

[X4 Pharmaceuticals](#) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer. The Company’s oral small molecule drug candidates antagonize the [CXCR4](#) pathway, which plays a central role in immune surveillance. X4’s most advanced product candidate is in a Phase 2/3 clinical trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease and is currently under investigation in multiple clinical trials in solid tumors. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA. For more information, visit x4.theyatesnetwork.com.

Contact:

Kathryn Morris
914-204-6412
kathryn@theyatesnetwork.com